HB Wealth Management LLC raised its position in shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) by 54.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,300 shares of the company’s stock after buying an additional 30,642 shares during the period. HB Wealth Management LLC’s holdings in Candel Therapeutics were worth $696,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also modified their holdings of CADL. Point72 DIFC Ltd purchased a new position in Candel Therapeutics during the 2nd quarter valued at about $31,000. FMR LLC purchased a new stake in Candel Therapeutics during the 3rd quarter worth approximately $46,000. MetLife Investment Management LLC acquired a new stake in Candel Therapeutics during the 3rd quarter worth approximately $87,000. Atom Investors LP purchased a new position in Candel Therapeutics in the 3rd quarter valued at approximately $103,000. Finally, Rhumbline Advisers acquired a new position in shares of Candel Therapeutics in the second quarter worth $143,000. 13.93% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.
Insiders Place Their Bets
In other news, insider Francesca Barone sold 13,534 shares of Candel Therapeutics stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total transaction of $97,715.48. Following the completion of the sale, the insider now directly owns 110,673 shares of the company’s stock, valued at approximately $799,059.06. The trade was a 10.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Garrett Nichols sold 13,935 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $4.56, for a total value of $63,543.60. Following the completion of the transaction, the insider now directly owns 100,547 shares in the company, valued at $458,494.32. This trade represents a 12.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 75,856 shares of company stock worth $470,044 in the last 90 days. Corporate insiders own 41.60% of the company’s stock.
Candel Therapeutics Stock Performance
Shares of Candel Therapeutics stock opened at $6.61 on Wednesday. The business has a 50-day simple moving average of $6.70 and a 200-day simple moving average of $6.28. Candel Therapeutics, Inc. has a one year low of $1.16 and a one year high of $14.60. The company has a market cap of $214.69 million, a PE ratio of -3.82 and a beta of -1.20.
Candel Therapeutics Profile
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Featured Articles
- Five stocks we like better than Candel Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- SAP’s Strong Momentum: A Bullish Setup for Investors
- How to Use Stock Screeners to Find Stocks
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Upcoming IPO Stock Lockup Period, Explained
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Want to see what other hedge funds are holding CADL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report).
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.